# Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

Study · id `cardio:ct-nct06164379` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06164379](<https://clinicaltrials.gov/study/NCT06164379>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06164379

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06164379. Randomized; double masking; primary purpose treatment. Start 2023-12-16 (anticipated); primary completion 2024-12-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06164379, source copy `cardio:ctgov-nct06164379-2023-12-11`, retrieved 2026-10-31)
- Planned start: 2023-12-16 (anticipated) (ClinicalTrials.gov record NCT06164379, source copy `cardio:ctgov-nct06164379-2023-12-11`, retrieved 2026-10-31)
- Primary completion: 2024-12-16 (anticipated) (ClinicalTrials.gov record NCT06164379, source copy `cardio:ctgov-nct06164379-2023-12-11`, retrieved 2026-10-31)
- Completion: 2024-12-16 (anticipated) (ClinicalTrials.gov record NCT06164379, source copy `cardio:ctgov-nct06164379-2023-12-11`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06164379, source copy `cardio:ctgov-nct06164379-2023-12-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06164379-2023-12-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
- Acronym: FAVOR
- Condition: Primary Aldosteronism
- Intervention (Drug): Finerenone
- Intervention (Drug): Spironolactone
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Primary aldosteronism (`cardio:primary-aldosteronism`)
- Registry intervention name matches this record: Finerenone (`cardio:finerenone`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: 78f4f325162a822358dd44bdfbf6cb2e8d28f00417491bcb3ac8e18950154e59
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
